Thomas Pike
Thomas Pike's purchase track record
Thomas Pike has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/29/2024 | FTRE | $248K | -8.4% | -12.8% | +13.9% |
| 8/23/2023 | FTRE | $505K | +29.5% | +43.4% | +12.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Barclays Upgrades Fortrea, Boosts Target to $23. Barclays has upgraded Fortrea Holdings to overweight and lifted its target price to $23. The upgrade follows a recent rise in the stock price and a mention of the company as an overrated pick in a Yahoo article. Analysts still see upside potential, with the average target of $21.04 and a 52‑week range that includes the new level. The stock’s high‑beta rating indicates it may continue to move sharply with market swings.
Transaction History
| MLM | ▲ Buy | Grant | 66 | $34K | 8/31/2026 | View on chart |
| MLM | ▲ Buy | Grant | 59 | $34K | 5/29/2026 | View on chart |
| MLM | ▲ Buy | Grant | 313 | $0 | 5/14/2026 | View on chart |
| MLM | ▲ Buy | Grant | 47 | $32K | 2/27/2026 | View on chart |
| MLM | ▲ Buy | Grant | 51 | $32K | 11/28/2025 | View on chart |
| MLM | ▲ Buy | Grant | 51 | $31K | 8/29/2025 | View on chart |
| MLM | ▲ Buy | Grant | 58 | $32K | 5/30/2025 | View on chart |
| MLM | ▲ Buy | Grant | 308 | $170K | 5/15/2025 | View on chart |
| MLM | ▲ Buy | Grant | 65 | $31K | 2/28/2025 | View on chart |
| FTRE | ▼ Sell | Open Market | 11,268 | $203K | 1/13/2025 | View on chart |
| FTRE | ▲ Buy | Option Exercise | 40,220 | $0 | 1/10/2025 | View on chart |
| MLM | ▲ Buy | Grant | 53 | $32K | 11/29/2024 | View on chart |
| MLM | ▲ Buy | Grant | 59 | $32K | 8/30/2024 | View on chart |
| FTRE | ▲ Buy | Option Exercise | 125,691 | $0 | 8/19/2024 | View on chart |
| FTRE | ▼ Sell | Tax Withholding | 52,602 | $1.2M | 8/19/2024 | View on chart |
| MLM | ▲ Buy | Grant | 55 | $32K | 5/31/2024 | View on chart |
| FTRE | ▲ Buy | Open Market | 10,000 | $248K | 5/29/2024 | View on chart |
| MLM | ▲ Buy | Grant | 293 | $170K | 5/16/2024 | View on chart |
| MLM | ▲ Buy | Grant | 52 | $30K | 2/29/2024 | View on chart |
| FTRE | ▲ Buy | Option Exercise | 40,220 | $0 | 1/9/2024 | View on chart |
| FTRE | ▼ Sell | Tax Withholding | 12,393 | $401K | 1/9/2024 | View on chart |
| MLM | ▲ Buy | Grant | 65 | $30K | 11/30/2023 | View on chart |
| MLM | ▲ Buy | Grant | 68 | $30K | 8/31/2023 | View on chart |
| FTRE | ▲ Buy | Open Market | 20,000 | $505K | 8/23/2023 | View on chart |
| MLM | ▲ Buy | Grant | 76 | $30K | 5/31/2023 | View on chart |
| MLM | ▲ Buy | Grant | 362 | $145K | 5/11/2023 | View on chart |
| MLM | ▲ Buy | Grant | 84 | $30K | 2/28/2023 | View on chart |
| MLM | ▲ Buy | Grant | 82 | $30K | 11/30/2022 | View on chart |
| MLM | ▲ Buy | Grant | 87 | $30K | 8/31/2022 | View on chart |
| MLM | ▲ Buy | Grant | 89 | $30K | 5/31/2022 | View on chart |
| MLM | ▲ Buy | Grant | 443 | $0 | 5/12/2022 | View on chart |
| MLM | ▲ Buy | Grant | 80 | $30K | 2/28/2022 | View on chart |
| MLM | ▲ Buy | Grant | 75 | $30K | 11/30/2021 | View on chart |
| MLM | ▲ Buy | Grant | 79 | $30K | 8/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Martin Marietta Earnings Loom as JPMorgan Cuts Price Target
Investors are focused on Martin Marietta's upcoming earnings release. JPMorgan recently maintained an Overweight rating on the stock but lowered its price target to $650. This move provides context for the current valuation ahead of the company's financial results.
Martin Marietta Earnings Loom as JPMorgan Cuts Price Target. Investors are focused on Martin Marietta's upcoming earnings release. JPMorgan recently maintained an Overweight rating on the stock but lowered its price target to $650. This move provides context for the current valuation ahead of the company's financial results.